All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Tarec El-Galaly, Aalborg University Hospital, Aalborg, DK. We asked, What impact does trial eligibility have on the generalizability of survival data?
What impact does trial eligibility have on the generalizability of survival data?
El-Galaly begins by discussing the Mayo Clinic trial that inspired this study and the increasing awareness in the lymphoma community of the generalizability of trials. He outlines the design of the trial and their findings, which matched those of the Mayo Clinic. Finally, he discusses matching clinical trial outcomes to real-world patients, and highlights a study presented at ASH.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox